ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows

DOW JONES NEWSWIRES Merck & Co.'s (MRK) first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth. Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin. Merck has said it expects to seek regulatory approval for five new products this year and in 2013, including potential treatments for osteoporosis, insomnia and a next-generation vaccine against a cancer-causing virus. The drug maker also has been focusing on areas such as hepatitis C and diabetes. Merck reported a profit of $1.74 billion, or 56 cents a share, up from $1.04 billion, or 34 cents, a year earlier. Excluding items such as acquisition-related and restructuring costs, earnings rose to 99 cents from 92 cents. Its March projection was earnings of 95 cents to 98 cents a share, below analysts' expectations at the time. Sales rose 1.3% to $11.73 billion, missing the $11.82 billion forecast from analysts polled by Thomson Reuters. Operating margin rose to 21.4% from 14.9%, reflecting a 14% drop in research and development costs. Pharmaceutical sales grew 2.7% to $10.08 billion. Singulair sales edged up 0.9%, while sales of Vytorin declined 8%. The animal-health business, which includes products for farm animals and pets, posted a 8.3% revenue increase. Sales in the consumer division--which includes over-the-counter allergy medicine Claritin and Coppertone skin-care products--rose 7.2%. Shares closed Thursday at $38.47 and were inactive premarket. The stock is up 2% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
05/23/201502:15:00MSD erhält positive Stellungnahme des CHMP zu Pembrolizumab...
05/22/201521:10:00MSD reçoit de la part du CHMP un avis favorable concernant le...
05/22/201507:12:00Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab...
05/22/201507:12:00MSD Receives Positive CHMP Opinion for Pembrolizumab for the...
05/20/201512:15:10What Is the S&P 500 Index?
05/18/201521:09:03The 30 Dow Jones Stocks
05/18/201512:18:57Endo to Buy Generics Maker Par Pharma for $8 Billion -- 4th Update
05/18/201511:05:26Endo to Buy Generics Maker Par Pharma for $8 Billion -- 3rd Update
05/18/201509:20:13Endo to Buy Par Pharma
05/18/201508:53:55Endo to Buy Generics Maker Par Pharma for $8 Billion -- 2nd Update
05/18/201508:00:00Merck to Present at the UBS Global Healthcare Conference
05/18/201507:44:29Endo to Buy Generics Maker Par Pharma for About $8 Billion...
05/17/201520:04:30M&A Fuels Fundraising
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/17/201508:04:02Big Pharma Stocks: Where to Invest Your Money Now
05/14/201509:04:02How a Strong Dollar Affects Pharmaceutical Stocks
05/13/201517:00:002015 ASCO Annual Meeting: New Data in 10 Different Cancers from...
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201517:50:13Statement of Changes in Beneficial Ownership (4)
05/11/201513:34:59Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad